Cyclacel Pharma Executive Compensation Details Revealed
Ticker: BGMSP · Form: DEFA14A · Filed: Jun 25, 2025 · CIK: 1130166
Sentiment: neutral
Topics: executive-compensation, stock-options, sec-filing
Related Tickers: CYCC
TL;DR
Cyclacel Pharma dropped its exec comp filing - check out those 2024 stock option awards!
AI Summary
Cyclacel Pharmaceuticals, Inc. filed a DEFA14A on June 25, 2025, detailing executive compensation for the fiscal years ending December 31, 2024, 2023, and 2022. The filing includes information on stock option awards and the year-end fair value of unvested awards granted to both principal executive officers (PEO) and non-PEO members. The company, formerly Xcyte Therapies Inc., is based in Berkeley Heights, NJ.
Why It Matters
This filing provides transparency into how Cyclacel Pharmaceuticals compensates its top executives, offering insights into the company's financial priorities and incentive structures.
Risk Assessment
Risk Level: low — This is a routine filing detailing executive compensation and does not indicate any immediate financial distress or significant operational changes.
Key Numbers
- 2024 — Fiscal Year (Executive compensation data reported for this year.)
- 2023 — Fiscal Year (Executive compensation data reported for this year.)
- 2022 — Fiscal Year (Executive compensation data reported for this year.)
Key Players & Entities
- Cyclacel Pharmaceuticals, Inc. (company) — Filer of the DEFA14A
- XCYTE THERAPIES INC (company) — Former name of Cyclacel Pharmaceuticals, Inc.
- 200 CONNELL DRIVE (location) — Business and mailing address of Cyclacel Pharmaceuticals, Inc.
- BERKELEY HEIGHTS (location) — City of Cyclacel Pharmaceuticals, Inc.'s address
- NJ (location) — State of Cyclacel Pharmaceuticals, Inc.'s address
FAQ
What specific stock option awards were granted to PEOs in 2024?
The filing indicates that stock option awards were granted to PEO members for the fiscal year 2024, with details on their value and vesting schedules expected within the full document.
What was the year-end fair value of unvested awards for non-PEO members in 2023?
The filing references 'YearEndFairValueOfUnvestedAwardsGrantedInTheApplicableFiscalYearMember' for non-PEO members for the fiscal year 2023, implying specific valuation data is present.
When did Cyclacel Pharmaceuticals change its name from XCYTE THERAPIES INC?
The date of the name change from XCYTE THERAPIES INC to Cyclacel Pharmaceuticals, Inc. was December 18, 2000.
What is the primary business address of Cyclacel Pharmaceuticals?
The business address is listed as 200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS, NJ 07922.
What is the SIC code for Cyclacel Pharmaceuticals?
The Standard Industrial Classification (SIC) code for Cyclacel Pharmaceuticals is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on June 25, 2025 regarding Cyclacel Pharmaceuticals, Inc. (BGMSP).